The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved delgocitinib cream, a topical Janus kinase (JAK) inhibitor, for treating moderate to severe Chronic Hand Eczema (CHE) in adults. This approval offers a new treatment option for those for whom topical corticosteroids are ineffective or unsuitable. CHE is a persistent inflammatory skin disease causing significant itch, pain, and disruptions to daily life.
This approval is significant for both LEO Pharma and individuals suffering from CHE. For LEO Pharma, it strengthens their position in the medical dermatology market and provides a valuable addition to their portfolio. For patients, it represents a much-needed new treatment approach, especially for those who haven’t found relief with existing topical corticosteroids. This approval also addresses the growing need for innovative solutions for this prevalent and burdensome condition.
Delgocitinib cream works by inhibiting JAK-STAT signaling, a key pathway in CHE’s development. The pathophysiology of CHE involves skin barrier dysfunction, inflammation, and changes in the skin microbiome. Clinical trials demonstrated the cream’s effectiveness in achieving primary and secondary endpoints, indicating significant improvement in CHE symptoms compared to a placebo. These trials included both short-term efficacy studies and longer-term evaluations of safety and efficacy. The availability of this topical treatment could potentially reduce the need for systemic treatments, minimizing the risk of broader side effects.
This MHRA approval marks a pivotal step forward in CHE management, offering new hope for patients experiencing the debilitating effects of this condition. Wider access to delgocitinib cream could improve patients’ quality of life by alleviating symptoms and enabling greater participation in daily activities. Further research and real-world data will help to refine the understanding of the cream’s long-term efficacy and safety profile, paving the way for personalized treatment strategies. This innovation holds promise for advancing the standard of care in dermatology and improving the lives of those affected by CHE.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
